Keywords: Renal cell carcinoma; Pazopanib; Real-world evidence; First-line therapy; Survival outcomes; Tolerability;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: Immune checkpoint inhibitor; Pazopanib; Renal cell carcinoma; Resistance; VEGF;
Keywords: Pazopanib; Formulation; Solubility; Bioavailability; Pharmaceutics;
Keywords: Phosphoproteomics; Kinase inhibitors; Drug resistance; Pazopanib; Dasatinib; Cell signalling;
Keywords: Cell penetrating peptides; TAT; Penetratin; POD; Peptide for ocular delivery; PEP-1; HCE: human corneal epithelial cell; Ocular Drug; Delivery; Cornea; Posterior eye segment; In vitro models; Eye drop; Topical instillation; Intravitreal injection; Ocular
Keywords: Myxofibrosarcoma; Head and neck; Proton beam therapy; Pazopanib;
Keywords: cabozantinib; depigmentation; dyspigmentation; hyperpigmentation; hypopigmentation; imatinib; ipilimumab; nivolumab; pazopanib; pembrolizumab; pigmentary; repigmentation; sorafenib; sunitinib; vitiligo; AE; adverse event; Bcr-abl; breakpoint cluster regio
Keywords: VEGF; Vascular Endothelial Growth Factor; MMP; Matrixmetalloproteinases; uPAR; UrokinasePlasminogen Activator Receptor; Ang-1; Angiotensin-1; TGF-β; Transforming Growth Factor-β; VEGFR; Vascular Endothelial Growth Factor Receptor; TKI; Tyrosine Kinase I
Keywords: Pazopanib; Renal cell carcinoma; Sorafenib; Sunitinib; Survival;
Keywords: Carcinoma; Renal cell; Sunitinib; Pazopanib; Vascular endothelial growth factor receptor;
Keywords: First-line mRCC treatment; mRCC prescribing preferences; Pazopanib; Sunitinib; TKI;
Keywords: kidney; carcinoma; renal cell; nephrectomy; pazopanib; neoadjuvant therapyAE, adverse event; CKD, chronic kidney disease; CT, computerized tomography; eGFR, estimated GFR; GFR, glomerular filtration rate; PN, partial nephrectomy; RCC, renal cell carcinoma
Keywords: Pazopanib; Sunitinib; Metastatic renal cell carcinoma (mRCC); Tumor flare; Growth rate; Treatment cessation; Treatment discontinuation; Tyrosine kinase inhibitors;
Keywords: Epithelial ovarian cancer; Cervical cancer; Endometrial cancer; Bevacizumab; Molecular signatures; Pazopanib; Nintedanib; Trebanabib
Keywords: Antiangiogenic agents; Metastatic renal cells cancer; Complete response; Sunitinib; Sorafenib; Pazopanib; Bevacizumab; Cytokines; Interferon;
Keywords: Renal cell carcinoma; Sorafenib; Pazopanib; Everolimus; Sunitinib; Bevacizumab; Axitinib; Antiangiogenic therapy; Treatment algorithm;
Keywords: Pazopanib; Angiogenesis; Soft tissue sarcoma; Vascular endothelial growth factor (VEGF); Targeted therapy; Tyrosine kinase inhibitor (TKI)
Keywords: Sarcoma; Solitary fibrous tumour; Pazopanib; Sunitinib; Tyrosine kinase; Chemotherapy;
Keywords: Cancer; Gastrointestinal perforation; Sorafenib; Sunitinib; Vandetanib; Axitinib; Pazopanib; Cediranib; Meta-analysis;
Targeting Bacteroides in Stool Microbiome and Response to Treatment With First-Line VEGF Tyrosine Kinase Inhibitors in Metastatic Renal-Cell Carcinoma
Keywords: Antibiotics; Pazopanib; Sunitinib; VEGF-TKI;
Doxorubicin-resistant pleomorphic liposarcoma with PDGFRA gene amplification is targeted and regressed by pazopanib in a patient-derived orthotopic xenograft mouse model
Keywords: Pleomorphic liposarcoma; PDOX; Pazopanib; PDGFRA; Targeted therapy; Temozolomide;
Adjuvant Antiangiogenic Agents in Post-nephrectomy Renal Cell Carcinoma: A Systematic Review and Meta-analysis
Keywords: Adjuvant chemotherapy; Renal cell carcinoma; Pazopanib; Sunitinib; Sorafenib; Tyrosine kinase inhibitors;
Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report
Keywords: Oncocytoma; Pazopanib; Renal preservation;
Molecular Dissection of Complete Response to Receptor Tyrosine Kinase Inhibition in Type II Papillary Renal Cell Carcinoma
Keywords: DNA damage repair; Fumarate hydratase; Hereditary leiomyomatosis and renal cell cancer; Pazopanib; Sunitinib;
Pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant, recurrent, pre-treated ovarian cancer - Results of the PACOVAR-trial
Keywords: Epithelial ovarian cancer; Platinum-resistant recurrence; Pazopanib; Cyclophosphamide; Metronomic therapy;
Original StudyFirst-Line PAzopanib in NOn-clear-cell Renal cArcinoMA: The Italian Retrospective Multicenter PANORAMA Study
Keywords: Chromophobe RCC; First-line treatment; nccRCC; Papillary RCC; Pazopanib;
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer
Keywords: mRCC; Dose reduction; Toxicity; Survival; Sunitinib; Pazopanib; First-line; Second-line;
Heterogeneity of circulating tumor cells (CTCs) in patients with recurrent small cell lung cancer (SCLC) treated with pazopanib
Keywords: TTF-1; CD56; VEGFR2; Immunofluorescence; CellSearch; SCLC; CTCs; Pazopanib;
Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia
Keywords: DDI; drug-drug interaction; β-EST; β-estradiol; HLM; human liver microsomes; IV-IVE; in vitro-in vivo extrapolation; KI; kinase inhibitor; 4MU; 4-methylumbelliferone; LAP; lapatinib; NSB; non-specific binding; PAZ; pazopanib; PRO; propofol; REG; r
Brain Metastasis Responsive to Pazopanib in Renal Cell Carcinoma: A Case Report and Review of the Literature
Keywords: Brain metastasis; Clear-cell mRCC; Pazopanib; Renal cell carcinoma; Tyrosine kinase inhibitors;
Pazopanib-mediated long-term disease stabilization after resection of a uterine leiomyosarcoma metastasis to the brain: A case report
Keywords: Uterine leiomyosarcoma; Brain metastasis; Pazopanib
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study
Keywords: GWAS; Ovarian cancer; Progression-free survival; Germline BRCA mutation; Pazopanib
Fuhrman Grade and Neutrophil-To-Lymphocyte Ratio Influence on Survival in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tyrosine Kinase Inhibitors
Keywords: Overall survival; Pazopanib; Prognostic factor; Sorafenib; Sunitinib;
Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma
Keywords: Advanced disease; Angiogenesis; Clinical benefit; Next-generation sequencing; Pazopanib;
Primitive Neuroectodermal Tumor of the Kidney:Â A Case Report
Keywords: CD99; Chemotherapy; Kidney; Pazopanib; Primitive neuroectodermal tumor;
Symptomatic Secondary Polycythemia Induced by Anti-VEGF Therapy for the Treatment of Metastatic Renal Cell Carcinoma: A Case Series and Review
Keywords: Axitinib; Bevacizumab; Erythropoietin; Hypoxia induced factor; Pazopanib; Phlebotomy; Sorafenib; Tyrosine kinase inhibitors;
Pazopanib as Third Line Therapy for Metastatic Renal Cell Carcinoma: Clinical Efficacy and Temporal Analysis of Cytokine Profile
Keywords: kidney neoplasms; cytokines; pazopanib; biological markers; mortalityCFSE, carboxyfluorescein succinimidyl ester; CR, complete response; DOT2, therapy duration in second line setting; HGF, hepatocyte growth factor; IL, interleukin; mRCC, metastatic renal
Phase II study of pazopanib as second-line treatment after sunitinib in patients with metastatic renal cell carcinoma: A Southern China Urology Cancer Consortium Trial
Keywords: Pazopanib; Metastatic renal cell carcinoma; Phase II; Delta-like ligand 4; Hypoxia-inducible factor;
Hypertension (HTN) as a potential biomarker of efficacy in pazopanib-treated patients with advanced non-adipocytic soft tissue sarcoma. A retrospective study based on European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 trial
Keywords: Sarcoma; Hypertension; Pazopanib; Biomarker;
Les nouveaux médicaments de la cancérologie
Keywords: afatinib; axitinib; cancérologie; dabrafénib; enzalutamide; mébutate d’ingénol; pazopanibafatinib; axitinib; dabrafenib; enzalutamide; ingenol mebutate; oncology; pazopanib
Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064)
Keywords: NSCLC; Advanced; Maintenance; Pazopanib; Phase III; Double blind;
Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity
Keywords: mTOR inhibitor; Pazopanib; Renal cell carcinoma; Sequential therapy; VEGF-targeted therapy
Incorporation of anti-angiogenesis therapy in the management of advanced ovarian carcinoma-Mechanistics, review of phase III randomized clinical trials, and regulatory implications
Keywords: Angiogenesis; Bevacizumab; Pazopanib; Cediranib; Trebananib; Nintedanib;
Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies
Keywords: Metastatic renal cell carcinoma; Mammalian target of rapamycin; Pazopanib; Targeted therapy; Tyrosine kinase inhibitor; Angiogenesis;
A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update
Keywords: Renal cell carcinoma; Pazopanib; Overall survival; Rank-preserving structural failure time model; Inverse probability of censor weighting;
Diagnostic dilemma of cardiac synovial sarcoma – Primary or secondary
Keywords: Cardiac; Synovial sarcoma; Primary; Ifosfamide; Pazopanib
Pazopanib as Second-Line Treatment After Sunitinib or Bevacizumab in Patients With Advanced Renal Cell Carcinoma: A Sarah Cannon Oncology Research Consortium Phase II Trial
Keywords: Pazopanib; Renal cell carcinoma; Sequential therapy; Tyrosine kinase inhibitors
A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
Keywords: Pazopanib; Urothelial cancer; VEGF tyrosine kinase inhibitors
An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non–Small-Cell Lung Cancer
Keywords: Non–small-cell lung cancer; Pazopanib; Pemetrexed; Cisplatin